CytomX Therapeutics (NASDAQ:CTMX) Issues Earnings Results
CytomX Therapeutics (NASDAQ:CTMX) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.13), Fidelity Earnings reports. CytomX Therapeutics had a negative return on equity of 77.05% and a negative net margin of 158.05%. The business had revenue of $10.71 million for the quarter, compared to analyst estimates of $23.58 million.
Shares of CytomX Therapeutics stock traded down $0.20 during trading on Friday, hitting $5.95. The stock had a trading volume of 538,700 shares, compared to its average volume of 437,329. The company has a debt-to-equity ratio of 0.26, a current ratio of 4.66 and a quick ratio of 4.66. CytomX Therapeutics has a fifty-two week low of $5.28 and a fifty-two week high of $19.75. The business has a fifty day moving average of $7.14 and a two-hundred day moving average of $9.47. The firm has a market cap of $281.99 million, a P/E ratio of -2.93 and a beta of 0.64.
A number of research analysts have issued reports on the company. Mizuho reiterated a “buy” rating and set a $16.00 price target on shares of CytomX Therapeutics in a research report on Monday, August 12th. Zacks Investment Research lowered CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 15th. ValuEngine upgraded CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. BidaskClub lowered CytomX Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, October 1st. Finally, Cowen restated a “buy” rating on shares of CytomX Therapeutics in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company’s stock. CytomX Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $20.14.
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Recommended Story: Resistance Level
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.